- Home
- BAFN vs EQ Comparison
BAFN vs EQ Comparison
Compare BAFN & EQ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BAFN
- EQ
- Stock Information
- Founded
- BAFN 1999
- EQ 2017
- Country
- BAFN United States
- EQ United States
- Employees
- BAFN N/A
- EQ N/A
- Industry
- BAFN Savings Institutions
- EQ Biotechnology: Pharmaceutical Preparations
- Sector
- BAFN Finance
- EQ Health Care
- Exchange
- BAFN Nasdaq
- EQ Nasdaq
- Market Cap
- BAFN 63.2M
- EQ 67.9M
- IPO Year
- BAFN N/A
- EQ 2018
- Fundamental
- Price
- BAFN $8.51
- EQ $1.70
- Analyst Decision
- BAFN
- EQ Hold
- Analyst Count
- BAFN 0
- EQ 2
- Target Price
- BAFN N/A
- EQ $1.00
- AVG Volume (30 Days)
- BAFN 21.9K
- EQ 2.8M
- Earning Date
- BAFN 10-23-2025
- EQ 11-12-2025
- Dividend Yield
- BAFN 3.79%
- EQ N/A
- EPS Growth
- BAFN 100.65
- EQ N/A
- EPS
- BAFN 1.89
- EQ N/A
- Revenue
- BAFN $78,211,000.00
- EQ $16,553,000.00
- Revenue This Year
- BAFN N/A
- EQ N/A
- Revenue Next Year
- BAFN N/A
- EQ N/A
- P/E Ratio
- BAFN $4.48
- EQ N/A
- Revenue Growth
- BAFN 0.67
- EQ N/A
- 52 Week Low
- BAFN $6.40
- EQ $0.27
- 52 Week High
- BAFN $19.75
- EQ $2.35
- Technical
- Relative Strength Index (RSI)
- BAFN 38.42
- EQ 56.36
- Support Level
- BAFN $8.40
- EQ $1.78
- Resistance Level
- BAFN $8.77
- EQ $2.02
- Average True Range (ATR)
- BAFN 0.33
- EQ 0.27
- MACD
- BAFN 0.15
- EQ -0.06
- Stochastic Oscillator
- BAFN 12.70
- EQ 22.94
About BAFN BayFirst Financial Corp.
BayFirst Financial Corp is a bank holding company, it generates its revenue from interest on loans and the gain-on-sale income derived from the sale of loans into the secondary market. The company serves a broad spectrum of individuals, families, and small businesses, supported by national business lines in residential and SBA lending and technology platforms. The primary source of funding for its loans is deposits. BayFirst measures performance through net interest income after provision for loan losses, return on average assets, and return on average common equity, while maintaining appropriate regulatory leverage and risk-based capital ratios. The company has various segment such as Real Estate(Residential, Commercial, and Construction & Land), Commercial and Industrial, Consumer.
About EQ Equillium Inc.
Equillium Inc is a clinical-stage biotechnology company engaged in developing novel therapeutics to treat severe autoimmune and inflammatory, or immuno-inflammatory, disorders with high unmet medical need. The company intends to commercialize its product candidates either independently or through partnerships, or otherwise monetize its pipeline through strategic transactions. Itolizumab (EQ001), a clinical-stage product candidate, is an anti-CD6 immune-modifying monoclonal antibody, or mAb, that selectively targets the CD6-ALCAM signaling pathway to downregulate pathogenic T effector cells while preserving T regulatory cells critical for maintaining a balanced immune response. The company's other clinical-stage and pre-clinical-stage candidates include EQ101 and EQ302.